IER5 Inhibitors
IER5 Inhibitors encompass a variety of chemical compounds that intervene in distinct cellular pathways, ultimately leading to a reduction in IER5 activity. Trichostatin A, a histone deacetylase inhibitor, suppresses IER5 by maintaining chromatin in a hypoacetylated and condensed state, which is less conducive to transcription. In a similar vein of epigenetic influence, 5-Azacytidine impedes DNA methylation, potentially decreasing IER5 expression by keeping its promoter region demethylated and transcriptionally inactive. Proteasome inhibition by MG-132 may indirectly lead to the downregulation of IER5 by triggering cellular stress responses that include feedback mechanisms to inhibit IER5. Additionally, various kinase inhibitors such as LY 294002, Wortmannin, Rapamycin, SB 203580, U0126, SP600125, PD 98059, and Roscovitine disrupt upstream signaling that normally results in the activation or upregulation of IER5. LY 294002 and Wortmannin obstruct the PI3K/Akt pathway, Rapamycin halts mTOR signaling, SB 203580 blocks p38 MAPK, while U0126 and PD 98059 target MEK in the ERK pathway, and SP600125 acts on JNK signaling. Each of these actions prevents the necessary signals for IER5 induction, thereby diminishing its activity.
These IER5 inhibitors operate through mechanisms that either prevent the initiation of IER5 expression or target the pathways that regulate its functional activity. Rapamycin's influence on the mTOR pathway suggests a decrease in IER5 activity by inhibiting the stimulatory pathways of cell growth and stress responses that upregulate IER5. Similarly, Roscovitine, by inhibiting cyclin-dependent kinases, disrupts cell cycle progression, potentially reducing IER5 activity related to cell cycle checkpoints. The collective action of these inhibitors highlights a strategic convergence on IER5, where the inhibition of key regulatory kinases and epigenetic modifiers converge to diminish the protein's activity without affecting its transcription or translation. The specificity with which these compounds target IER5 underscores the intricate network of signaling pathways and regulatory mechanisms that dictate the functional landscape of this protein, and their targeted inhibition of IER5 reflects a nuanced understanding of its role in cellular processes.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor that prevents chromatin remodeling. IER5 expression is regulated by chromatin acetylation levels; thus, inhibiting histone deacetylases can diminish IER5 expression by maintaining a hypoacetylated state of chromatin, which is associated with condensed, transcriptionally inactive chromatin. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine, a DNA methyltransferase inhibitor, leads to the hypomethylation of DNA. DNA methylation is a key epigenetic mechanism that can silence gene expression. By inhibiting methylation, 5-Azacytidine can diminish IER5 expression by preventing the methylation of its promoter region, which would otherwise suppress transcription. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG-132 is a proteasome inhibitor that interferes with the degradation of ubiquitinated proteins. By inhibiting the proteasome, MG-132 can lead to the accumulation of regulatory proteins that induce cellular stress responses, potentially diminishing IER5 activity as part of a negative feedback loop to mitigate stress-induced damage. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY 294002 is a phosphoinositide 3-kinases (PI3K) inhibitor that blocks signaling through the PI3K/Akt pathway. Since IER5 is known to be induced by growth factors that signal through this pathway, inhibition by LY 294002 could lead to a decrease in IER5 levels by blocking the upstream signals required for its induction. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor that impairs cell growth and proliferation by blocking the mTOR pathway. Given that IER5 is involved in the stress response and cell cycle regulation, rapamycin can indirectly diminish IER5 activity by inhibiting the pathways that stimulate its expression during cell growth and stress responses. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 203580 is a specific inhibitor of p38 MAPK, a kinase involved in the response to stress and cytokines. By inhibiting p38 MAPK activity, SB 203580 can diminish IER5 activity, as IER5 is implicated in stress response pathways that are regulated by p38 MAPK. This disruption can lead to decreased activation of IER5-dependent stress response mechanisms. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK, which is upstream of the ERK MAPK pathway. Since IER5 can be induced by ERK pathway activation, using U0126 to inhibit MEK could lead to a decrease in IER5 activity by preventing its induction via the ERK signaling pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK (c-Jun N-terminal kinase), which is involved in the activation of transcription factors that regulate stress responses and apoptosis. Inhibition of JNK by SP600125 could diminish IER5 activity by blocking the signaling required for its stress-induced expression. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is an irreversible inhibitor of PI3K. Wortmannin can diminish IER5 activity by blocking the PI3K/Akt pathway and thereby reducing the signals necessary for IER5 expression in response to growth factors and stress stimuli. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 is a specific inhibitor of MEK, which acts upstream of the ERK MAPK pathway. By inhibiting the activation of MEK, PD 98059 can diminish IER5 activity by reducing the signals that promote IER5 expression through the ERK signaling cascade. | ||||||